Gut Microbiome Composition Balancing Prebiotic Efficacy and Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional prebiotics often cause gastrointestinal discomfort and are not effective in selectively stimulating the growth of beneficial gut bacteria like Akkermansia muciniphila, Lactobacilli, and Bifidobacteria, while polyphenols with high chlorogenic acid content face challenges in consumer-friendly formulations due to bitter flavors.
Innovation Solution
A gut microbiome modulating composition comprising a blend of non-digestible oligosaccharides (NDOs) with a high degree of polymerization and polyphenols, such as green coffee bean extract (GCBE) rich in chlorogenic acid, formulated to promote the growth of beneficial bacteria and improve gut health without significant discomfort.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prebiotics are administered to modulate gut microbiome, then beneficial bacteria growth is stimulated, but gastrointestinal discomfort and laxative effects occur
Solution Approach 1:
The patent changes the molecular parameters of oligosaccharides by selecting specific types (xylooligosaccharides, fructooligosaccharides, galactooligosaccharides) with controlled degrees of polymerization (DP 3-10), and combines them with polyphenols in specific ratios (1:4 to 4:1). This parameter optimization allows effective microbiome modulation while reducing gastrointestinal side effects compared to conventional prebiotics
Solution Approach 2:
The invention creates a composite prebiotic material combining oligosaccharides with polyphenols (such as chlorogenic acid, epigallocatechin gallate, or resveratrol) in a synergistic formulation. This composite approach enhances beneficial effects on gut bacteria (Akkermansia, Bifidobacterium, Lactobacillus) while the polyphenol component helps mitigate gastrointestinal discomfort and laxative effects
2Reliability
If high doses of prebiotics are used to achieve therapeutic effects, then microbiome modulation improves, but laxative effects and gastrointestinal symptoms increase
Solution Approach 1:
The patent optimizes the dosage parameters by administering the prebiotic composition at 0.5-10 grams per day of oligosaccharides combined with polyphenols, which is lower than conventional prebiotic doses. The specific molecular structure parameters (degree of polymerization, sugar composition) enhance efficacy per unit dose, reducing the need for high dosing and thereby minimizing laxative effects while maintaining obesity management benefits
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively increases the abundance of Akkermansia muciniphila, Lactobacilli, and Bifidobacteria, enhances short-chain fatty acid production, and modulates immune response, providing protective effects against obesity-related diseases.
Implementation Method 1
a gut microbiome modulating composition comprises a blend of non-digestible oligosaccharides (NDOs) with a high degree of polymerization and polyphenols, such as chlorogenic acid, which selectively stimulates the growth of beneficial bacteria like Akkermansia muciniphila, Lactobacillus, and Bifidobacterium
Data Source
AI summary
Various embodiments of a gut microbiome modulating composition comprises a blend of a polyphenol and an oligosaccharide. Various embodiments of the polyphenol may comprise at least approximately 5% by weight chlorogenic acid. Various embodiments of the oligosaccharides may be standardized to a degree of polymerization of at least three to reduce digestibility. Administration of an effective amount of the gut microbiome modulating composition to a person or animal may stimulate the growth of at least one of Akkermansia muciniphila, Lactobacillus, and Bifidobacterium bacteria in the colon, which may reduce permeability of the colon, increases short chain fatty acid production in the colon, and/or modulate causes immunomodulation of human colon cells. The gut microbiome modulating composition may provide protective effects against obesity-related chronic diseases.